Shares of ChemoCentryx Inc. (NASDAQ:CCXI) fell 2.8% during mid-day trading on Thursday . The company traded as low as $4.42 and last traded at $4.52, with a volume of 93,821 shares. The stock had previously closed at $4.65.

A number of brokerages recently issued reports on CCXI. Zacks Investment Research downgraded ChemoCentryx from a “buy” rating to a “hold” rating in a research report on Monday, May 16th. Cowen and Company reissued a “hold” rating on shares of ChemoCentryx in a research report on Thursday, May 19th.

The company’s 50-day moving average price is $4.87 and its 200 day moving average price is $3.89. The stock’s market capitalization is $200.19 million.

ChemoCentryx (NASDAQ:CCXI) last posted its earnings results on Tuesday, May 10th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.27) by $0.07. On average, equities analysts anticipate that ChemoCentryx Inc. will post ($0.35) earnings per share for the current fiscal year.

In related news, Director Thomas A. Edwards acquired 50,000 shares of ChemoCentryx stock in a transaction dated Tuesday, May 17th. The shares were acquired at an average cost of $4.05 per share, for a total transaction of $202,500.00. Following the completion of the transaction, the director now directly owns 91,977 shares of the company’s stock, valued at $372,506.85. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Thomas A. Edwards acquired 25,000 shares of ChemoCentryx stock in a transaction dated Monday, May 16th. The stock was bought at an average price of $4.05 per share, for a total transaction of $101,250.00. Following the completion of the transaction, the director now directly owns 41,977 shares of the company’s stock, valued at $170,006.85. The disclosure for this purchase can be found here.

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.